News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

ADMA Biologics, Inc. Completes Enrollment of Phase 3 Study for RI-002


11/4/2013 10:03:55 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

RAMSEY, N.J.--(BUSINESS WIRE)--ADMA Biologics, Inc. (OTCQB:ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to market specialty plasma-based biologics for the treatment and prevention of certain infectious diseases, today announced the completion of enrollment for its Phase III clinical study of RI-002. This study is designed to evaluate the efficacy and safety of RI-002 as a novel immune globulin for the treatment of patients who are affected by Primary Immune Deficiency Diseases (PIDD). ADMA expects to have preliminary Phase III data in the fourth quarter of 2014.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES